Cel-Sci Corporation (
NYSEAMERICAN:CVM -
Get Free Report) was down 3% on Thursday . The company traded as low as $8.89 and last traded at $8.99. Approximately 21,439 shares were traded during trading, a decline of 73% from the average daily volume of 77,985 shares. The stock had previously closed at $9.27.
Cel-Sci Price Performance
The stock has a 50 day simple moving average of $9.77 and a two-hundred day simple moving average of $6.87. The firm has a market cap of $61.85 million, a PE ratio of -0.92 and a beta of 0.52. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.37 and a current ratio of 0.47.
Institutional Investors Weigh In On Cel-Sci
A hedge fund recently raised its stake in Cel-Sci stock. MAI Capital Management raised its position in Cel-Sci Corporation (NYSEAMERICAN:CVM - Free Report) by 229.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 526,480 shares of the company's stock after buying an additional 366,880 shares during the period. MAI Capital Management owned about 0.63% of Cel-Sci worth $121,000 at the end of the most recent reporting period. 12.08% of the stock is currently owned by hedge funds and other institutional investors.
About Cel-Sci
(
Get Free Report)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cel-Sci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cel-Sci wasn't on the list.
While Cel-Sci currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
